Dan­ish biotech gears up for Phase IIb hidradeni­tis sup­pu­ra­ti­va tri­al fol­low­ing ear­ly clin­i­cal re­sults

MC2 Ther­a­peu­tics’ drug can­di­date for hidradeni­tis sup­pu­ra­ti­va has shown hints of ef­fi­ca­cy po­ten­tial in a Phase IIa tri­al, spark­ing plans for Phase IIb de­vel­op­ment with a pri­ma­ry end­point that may be a high­er bar than pre­vi­ous ap­provals.

The Dan­ish biotech ob­tained ex­clu­sive glob­al rights, ex­cept for main­land Chi­na, Hong Kong, Macau and Tai­wan, to the oral heat shock pro­tein 90 (HSP-90) in­hibitor, dubbed MC2-32, from Re­gran­ion last month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER